Intervacc IVACC.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker IVACC.ST. It has been listed since 7 April 2017. In the fiscal year to 31 December 2025, it reported revenue of SEK 20.1m and a net loss of SEK 80.8m. At that date it held total assets of SEK 294.4m and shareholders' equity of SEK 274.9m.

Intervacc AB engages in the development of novel veterinary vaccines. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2017-04-07. The company develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The firm operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. The company offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Hakan BjoerklundIndependent Chairman of the BoardSEK 314,000
• Mr. Jonas SohlmanChief Executive OfficerSEK 2.8m
• Mr. Jan PerssonChief Financial Officer
• Mr. Patrik HellbergChief Information Officer
• Mr. Andreas JohanssonVice President - Supply Chain Management, since 2022
• Mr. Andrew WallerChief Scientific Officer, since 2020
• Mr. Emil BillbaeckIndependent DirectorSEK 76,000
• Prof. Jan-Ingmar FlockIndependent Director, since 2023SEK 146,000
• Ms. Lisen FredricsonIndependent DirectorSEK 146,000
• Mr. Lennart JohanssonIndependent DirectorSEK 146,000
• Ms. Camilla MccarthyIndependent DirectorSEK 146,000
• Mr. Mathias UhlenIndependent DirectorSEK 76,000

Overall

10

Environment

12

Social

7

Governance

13

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.